One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes

被引:4
作者
Taybani, Zoltan J. [1 ]
Botyik, Balazs [1 ]
Gyimesi, Andras [1 ]
Katko, Monika [2 ]
Varkonyi, Tamas [3 ]
机构
[1] Dr Rethy Pal Member Hosp, Bekes Cty Cent Hosp, Dept Endocrinol, Bekescsaba, Hungary
[2] Univ Debrecen, Fac Med, Dept Internal Med, Div Endocrinol, Debrecen, Hungary
[3] Univ Szeged, Dept Internal Med, Szeged, Hungary
关键词
diabetes; IDegLira; overtreatment; simplification; DEINTENSIFICATION; THERAPY; GLARGINE; REGIMEN;
D O I
10.1002/edm2.390
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionThis study aimed to investigate the sustained safety and efficacy of insulin treatment simplification with IDegLira in patients with type 2 diabetes and an HbA1c <= 7.5% (58 mmol/mol) during a 12-month follow-up. MethodsSeventy-two adults with type 2 diabetes and an HbA1c <= 7.5% (58 mmol/mol) treated with multiple daily insulin injections (MDI) participated in the trial (age 63.8 +/- 9.5 years, HbA1c 6.4 +/- 0.7%, [46 +/- 8 mmol/mol] body weight 92.95 +/- 18.83 kg, total daily insulin dose: 43.21 +/- 10.80 units; mean +/- SD). Previous insulins were stopped, and once daily IDegLira was started. IDegLira was titrated by the patients to achieve a self-measured prebreakfast plasma glucose concentration of >= 5 mmol/L to <= 6 mmol/L. ResultsAfter 12 months, good glycaemic control was maintained, while body weight decreased significantly. Mean HbA1c changed to 6.2 +/- 0.8% (44 +/- 9 mmol/mol) (p = .109) and body weight changed by -3.89 kg to 89.06 +/- 18.61 kg (p < .0001). The simplified treatment was safe and well-tolerated. Percentage of patients experiencing at least one episode of hypoglycaemia was 49% during the month before simplification and 17% during the last 3 months of the follow-up. ConclusionsInsulin treatment simplification with IDegLira in selected patients with type 2 diabetes is safe, maintains adequate glycaemic control and is associated with weight loss over 12 months.
引用
收藏
页数:7
相关论文
共 21 条
[1]   Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes [J].
Abdelhafiz, A. H. ;
Sinclair, A. J. .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (04) :444-450
[2]   9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022 [J].
American Diabetes Association Professional Practice Committee .
DIABETES CARE, 2022, 45 :S125-S143
[3]  
[Anonymous], 2017, Diabetologia Hungarica
[4]   Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial [J].
Billings, Liana K. ;
Doshi, Ankur ;
Gouet, Didier ;
Oviedo, Alejandra ;
Rodbard, Helena W. ;
Tentolouris, Nikolaos ;
Gron, Randi ;
Halladin, Natalie ;
Jodar, Esteban .
DIABETES CARE, 2018, 41 (05) :1009-1016
[5]  
Giugliano D, 2021, DIABETES RES CLIN PR, V178, DOI [10.1016/j.diabres.2021.1089580168-8227/, 10.1016/j.diabres.2021.108958]
[6]   Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial [J].
Giugliano, Dario ;
Longo, Miriam ;
Caruso, Paola ;
Di Fraia, Rosa ;
Scappaticcio, Lorenzo ;
Gicchino, Maurizio ;
Petrizzo, Michela ;
Bellastella, Giuseppe ;
Maiorino, Maria Ida ;
Esposito, Katherine .
DIABETES CARE, 2021, 44 (06) :1353-1360
[7]   Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes [J].
Gough, Stephen C. L. ;
Jain, Rajeev ;
Woo, Vincent C. .
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (01) :7-19
[8]   Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update [J].
Hanefeld, Markolf ;
Fleischmann, Holger ;
Siegmund, Thorsten ;
Seufert, Jochen .
DIABETES THERAPY, 2020, 11 (08) :1645-1666
[9]   A 52-Week, Multinational, Open-Label, Parallel-Group, Noninferiority, Treat-to-Target Trial Comparing Insulin Detemir with Insulin Glargine in a Basal-Bolus Regimen with Mealtime Insulin Aspart in Patients with Type 2 Diabetes [J].
Hollander, Priscilla ;
Cooper, John ;
Bregnhoj, Jesper ;
Pedersen, Claus Bang .
CLINICAL THERAPEUTICS, 2008, 30 (11) :1976-1987
[10]   Overtreatment and Deintensification of Diabetic Therapy among Medicare Beneficiaries [J].
Maciejewski, Matthew L. ;
Mi, Xiaojuan ;
Sussman, Jeremy ;
Greiner, Melissa ;
Curtis, Lesley H. ;
Ng, Judy ;
Haffer, Samuel C. ;
Kerr, Eve A. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 (01) :34-41